Astra Zeneca will present survival data from four phase 3 studies during Presidential Symposia at the European Cancer Congress ESMO 2026, with a particular focus on the drugs Sone-Ve, Imfinzi, Tagrisso, and Orpathys. #AstraZeneca #Cancerforskning #Overlevnadsdata (translated)





